FY2030 Earnings Forecast for SGMO Issued By HC Wainwright

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Sangamo Therapeutics in a report issued on Tuesday, February 10th. HC Wainwright analyst P. Trucchio forecasts that the biopharmaceutical company will post earnings of $0.67 per share for the year. HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.46) per share.

A number of other equities research analysts have also commented on the stock. Barclays reaffirmed an “equal weight” rating and issued a $1.00 price objective (down from $5.00) on shares of Sangamo Therapeutics in a research note on Friday, November 7th. Wall Street Zen cut shares of Sangamo Therapeutics to a “strong sell” rating in a research report on Saturday, January 31st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sangamo Therapeutics in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Sangamo Therapeutics has a consensus rating of “Hold” and a consensus target price of $4.33.

Sangamo Therapeutics Stock Performance

NASDAQ:SGMO opened at $0.39 on Wednesday. Sangamo Therapeutics has a fifty-two week low of $0.35 and a fifty-two week high of $1.24. The company has a 50 day simple moving average of $0.44 and a two-hundred day simple moving average of $0.51. The company has a market capitalization of $131.23 million, a PE ratio of -0.89 and a beta of 1.28.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Sangamo Therapeutics by 23.9% in the third quarter. Vanguard Group Inc. now owns 11,615,150 shares of the biopharmaceutical company’s stock valued at $7,817,000 after acquiring an additional 2,240,422 shares during the period. Wasatch Advisors LP increased its stake in Sangamo Therapeutics by 17.7% during the 2nd quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company’s stock valued at $4,376,000 after purchasing an additional 1,215,653 shares in the last quarter. Geode Capital Management LLC increased its stake in Sangamo Therapeutics by 17.6% during the 4th quarter. Geode Capital Management LLC now owns 3,866,026 shares of the biopharmaceutical company’s stock valued at $1,624,000 after purchasing an additional 579,550 shares in the last quarter. GSA Capital Partners LLP lifted its stake in shares of Sangamo Therapeutics by 63.1% in the third quarter. GSA Capital Partners LLP now owns 3,662,478 shares of the biopharmaceutical company’s stock valued at $2,466,000 after buying an additional 1,417,029 shares in the last quarter. Finally, Two Sigma Investments LP grew its holdings in shares of Sangamo Therapeutics by 182.7% during the third quarter. Two Sigma Investments LP now owns 2,479,186 shares of the biopharmaceutical company’s stock valued at $1,669,000 after buying an additional 1,602,107 shares during the last quarter. 56.92% of the stock is owned by institutional investors and hedge funds.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.